Objective: This study aims to examine cross-sectional and longitudinal relations between dietary intake of isoflavones and bone mineral density (BMD) at the lumbar spine (LS) and femoral neck (FN) in black, white, Chinese, and Japanese women during the menopausal transition.
P hytoestrogensVheterocyclic phenols found in plant foodsVconsist mainly of isoflavones, lignans, and coumestans. These compounds, especially the isoflavone class, gained prominence because of their associations with lower rates of hormone-dependent malignancies and have since been associated with prevention of other chronic diseases, including osteoporosis. 1<4 Isoflavones may benefit bones because they have positive effects on the osteoblast cell line (favoring proliferation, differentiation, and mineralization) and hinder osteoclast and adipocyte generation. 5 Some bone effects of isoflavones depend on estrogen receptors for mediation, whereas others are estrogen receptorYindependent. Isoflavones bind to estrogen receptor-> and estrogen receptor-A and are predominantly agonists based on transcriptional activation assays. 6, 7 However, predicting the effects of isoflavones on estrogen pathways is challenging because of the following reasons: compounds vary in their affinity for estrogen receptor-> and estrogen receptor-A; conformational effects on estrogen receptors differ; agonist or antagonist properties may depend on circulating estradiol levels or phytoestrogen concentrations; and isoflavones modify the metabolism and bioavailability of endogenous sex steroids in ways that may either increase or decrease endogenous hormone levels or bioavailability. 3, 4 ,6<10 Some isoflavones are potent antioxidants, a characteristic that could also promote favorable bone balance. 4, 11, 12 Although isoflavones could be advantageous to bones via many biological pathways, results of observational and interventional studies of isoflavones using bone mineral density (BMD) outcomes remain equivocal. 13 A meta-analysis of 11 randomized controlled trials of soy isoflavone supplements in postmenopausal women concluded that a statistically significant gain in lumbar spine (LS), but not hip, BMD resulted from supplement use. 14 However, four subsequent large randomized controlled trials of soy isoflavone supplements in postmenopausal women discerned no whole-body or regional BMD effects of these compounds. 15<18 Substantial doses of isoflavones (equal to or greater than the amounts in many Asian diets) were used in most interventions, making inadequate dose an improbable explanation for the null findings. 14<17 Other postulated reasons for the null effects of interventions include the following: isolated supplements may not have the same effects as high-isoflavone diets (eg, because of differences in the bioavailability or representation of specific compounds); long durations of exposure may be needed (as in lifelong dietary intake); and timing of exposure during the life course might matter. Although observational studies have their own set of limitations, complementary information may be obtained from cohort studies of diet and bone outcomes.
Longitudinal cohort studies of the bone density effects of isoflavones are few and yield results that vary by sex, menopausal transition stage, and bone site measured. 19<23 Two large longitudinal studies of soy foods and fractures among postmenopausal women in China reported a lower risk of any fracture 24 or hip fracture 25 with higher intake, suggesting that long-term consumption of dietary soy isoflavones has a boneprotective effect. To our knowledge, no prior study has investigated the relation between isoflavones and bone loss during the menopausal transition.
This study uses data from the Study of Women's Health Across the Nation (SWAN), a study of the menopausal transition in a multiracial/ethnic sample, and from the SWAN Phytoestrogen Study, a project that has greatly expanded the SWAN dietary phytonutrient data. 26, 27 In these analyses, we examine the cross-sectional relations between usual dietary consumption of isoflavones and BMD at SWAN baseline, and the longitudinal association between dietary isoflavones and change in BMD. We have previously demonstrated that during the 10-year interval surrounding the final menstrual period (FMP), rates of change in LS and femoral neck (FN) BMD were divisible into three linear phases with distinctive slopes. 28 Specifically, during the period between 5 years before the FMP and 1 year before the FMP (Bpretransmenopausal phase[), there was no measurable change in BMD. BMD loss began 1 year in advance of the FMP (Btransmenopausal phase[) and slowed, but did not cease, 2 years after the FMP (Bpostmenopausal phase[). The present longitudinal investigation asks whether women with higher dietary intake of isoflavones, compared with those with lower intake, have different rates of BMD loss in these three intervals surrounding the FMP.
METHODS

Study sample
The study sample is from the SWAN Phytoestrogen Ancillary Study, which was conducted within the parent SWAN cohort. 26, 27 Women were enrolled in SWAN between January 1996 and February 1997. Entry criteria were as follows: aged between 42 and 52 years, with intact uterus and at least one intact ovary, not using hormone therapy, had at least one menstrual period in the 3 months before screening, and selfidentification as a member of one of five eligible racial/ethnic groups. Boston, Chicago, Detroit, Pittsburgh, Los Angeles, Newark, and Oakland were the seven clinical sites, each of which enrolled white women. Boston, Chicago, Detroit, and Pittsburgh enrolled black women. Los Angeles, Newark, and Oakland enrolled Japanese, Hispanic, and Chinese women, respectively. The SWAN baseline cohort sample size was 3,302. SWAN collected dietary data at baseline and on annual follow-up visits 5 and 9. The SWAN Phytoestrogen Substudy excluded the Newark SWAN site because of high attrition and lack of dietary data on visit 9; 2,870 women were eligible for the Phytoestrogen Study at the remaining six sites. At baseline, participants were excluded from the Phytoestrogen Study for the following reasons: no diet assessment (n = 17); intake of less than 4 or greater than 17 solid foods per day (n = 130); skipped more than 10 food items on the Food Frequency Questionnaire (FFQ; n = 1); and calculated daily calorie intake of less than 500 kcal or more than 5,000 kcal (n = 24). If these dietary exclusion criteria were met at later visits, participants were censored at that time. Thus, the maximal SWAN Phytoestrogen Study sample sizes were 2,721 at baseline, 1,905 on follow-up visit 5, and 1,677 on follow-up visit 9. The current study of phytoestrogens and BMD also required that participants have BMD data and no bone-based exclusions. The Newark (already excluded from the Phytoestrogen Study) and Chicago sites did not measure BMD; a maximum of 2,413 participants were included in the SWAN bone density subcohort. The current analysis includes BMD data (baseline through follow-up visit 10, completed in February 2008) from Phytoestrogen Study participants who had an observed natural FMP during that time interval and who were not taking hormone therapy or other pharmacological agents that may affect bones at any time during the observation period, resulting in an analytic sample size of 853. All sites obtained Institutional Review Board approvals for study protocols, and all participants gave written informed consent.
Outcomes
LS and FN BMD (g/cm 2 ) were measured annually using Hologic instruments (Hologic Inc, Waltham, Massachusetts). Three sites used Hologic 4500A models throughout. Two sites upgraded from 2000 to 4500A models on follow-up visit 8; they scanned 40 women on both old and new machines to develop cross-calibration regression equations. 28 A standard quality control program, conducted with Synarc Inc (San Francisco, CA), included daily phantom measurements, six monthly cross-calibrations with a circulating anthropomorphic spine standard, local site review of all scans, central review of scans that met problem-flagging criteria, and central review of a 5% random sample of scans. Short-term in vivo measurement variability was 0.014 g/cm 2 (1.4%) for the LS and 0.016 g/cm 2 (2.2%) for the FN.
Primary exposure variables: dietary phytoestrogens
SWAN originally estimated dietary isoflavone intake based on the limited nutrient databases available through 1994. 29, 30 By adding nutrient information available through 2008, the SWAN Phytoestrogen Study greatly expanded phytoestrogen ascertainment. 27 In brief, the SWAN dietary assessment is a three-component interviewer-administered instrument that gauges usual food consumption during the past year. It consists of (1) a full FFQ, (2) an BEthnic Foods Page, [ and (3) open-ended questions. The English-language FFQ contains a 103-item core food list based on the Second National Health and Nutrition Examination Survey. 31 The Chinese and Japanese versions include the same 103-item core food list plus 12 to 16 foods appropriate for each group (Ethnic Foods Page). Finally, all participants were asked about other foods eaten at least weekly. The SWAN Phytoestrogen Study constructed a phytonutrient database using all available phytonutrient data through 2008. The exposure used in the current analysis is the total daily intake of isoflavones (sum of daidzein, genistein, formononetin, and glycetin). Total dietary calorie intake (in kilocalories) was also computed.
Other predictors
FMP date, assessed by annual interview, was defined as the menstrual bleeding date during the visit immediately before the first visit when the participant was classified as postmenopausal (had 12 mo of amenorrhea). The number of months before or after the FMP that the BMD was taken was computed using the month and year of the FMP and the month and year of each annual BMD assessment. Age (years), self-defined race/ ethnicity (black, white, Chinese, Japanese), hormone therapy use (yes vs no, time-varying), and use of bone-active medication (yes vs no, time-varying) were obtained using annual standardized interviews. Menopausal transition stages (crosssectional analysis only based on reported bleeding patterns) were defined as premenopausal (regular menses, no change in pattern) and early perimenopausal (cycles more irregular than they had been but without gaps in cycles of 3 mo or more). Weight (kilograms, time-varying) and height (meters) were assessed annually using calibrated scales and stadiometers. Body mass index (BMI; weight in kilograms / [height in meters] 2 ) was calculated annually. Because diet was not measured annually, total calorie intake (continuous) was interpolated for visits at which diet was not measured (described below). For all covariates, values corresponding to the beginning of each segment of the piecewise model were used in analyses (see BData Analysis[).
Interpolation of dietary intake variables
Diet was assessed at SWAN baseline and on follow-up visits 5 and 9, whereas BMD outcomes were measured annually. To handle this difference in measurement schedules, we interpolated (one at a time) dietary variables (isoflavones and total calorie intake [in kilocalories]) using random-effects modeling; dietary variables were log-transformed because of right skewness and modeled as a function of time on study. 32 Models were stratified by race/ethnicity because of racial/ ethnic differences in isoflavone consumption. LOESS (locally estimated scatterplot smoothing) curves indicated linear time trends; thus, each model included a random (woman-specific) intercept and a slope for time on study. The woman-specific regression coefficients are weighted means of coefficients from the full sample and coefficients from each participant's data only. 33 Predictors other than time on study were not used in the final interpolation because they did little to improve prediction, but missing data reduced the sample size. To assess the performance of interpolation models, we compared fitted values with observed values for visits at which diet was actually assessed (baseline and follow-ups 5 and 9). R values between fitted and observed values, accounting for withinwoman correlation, ranged from 0.978 to 0.996, indicating excellent agreement. 34 Linear regressions of observed values on fitted values indicated no systematic bias: intercepts were close to 0, and slopes were close to 1. Finally, LOESS curves for observed dietary variable values in relation to time on study overlapped considerably with corresponding curves for fitted values. We interpolated (ie, imputed) logged dietary variables for visits at which diet was not assessed, using participant-specific intercept and slope coefficients and the relevant value of time on study for each study visit at which diet was not assessed. Owing to the high agreement between observed and fitted values, we did not use multiple imputation.
Data analysis Coding of dietary exposure variables
All analyses were conducted using SAS version 9.2. Intakes of daidzein, genistein, formononetin, and glycetin were summed to obtain total isoflavone exposure. Isoflavone distribution was strongly bimodal, with almost no overlap in intake between Chinese and Japanese (higher), and between white and black (lower). Therefore, we constructed Asian and non-Asian isoflavone tertiles. In longitudinal analyses, we used time-varying membership in the highest tertile of intake as the primary exposure but maintained baseline tertile cutpoints to identify high-intake women on follow-up visits.
Cross-sectional analyses
We examined whether isoflavone intake (categorized into tertiles) was associated with baseline BMD. For comparability with longitudinal results, only data from women in the longitudinal analysis were included. We used race/ethnicitystratified linear regression to adjust for age (continuous), BMI (continuous), total calorie intake (in kilocalories; continuous), supplemental calcium use (any vs none), supplemental vitamin D use (any vs none), cigarette use (any current vs other), alcohol use (any current vs other), and menopausal transition stage (early perimenopausal vs premenopausal). We tested for interaction between isoflavone intake and menopausal transition stage. Findings are presented as multiply adjusted least-squares mean estimated BMD values in each tertile of isoflavone consumption; we conducted a test of trend across tertiles.
Longitudinal analysis
To analyze whether phytonutrient intake (categorized into tertiles) was associated with longitudinal trajectories of BMD anchored on the date of the FMP, we used mixed-effects regression. We fitted piecewise linear models to repeated measurements of baseline-normalized LS or FN BMD as functions of time before or after the FMP, using linear splines with fixed knots at 1 year before and 1 year after the FMP. This piecewise linear model, previously developed, identified three phases of bone loss in relation to the date of the FMP: pretransmenopausal (interval spanning from 5 y before the FMP to 1 y before the FMP), transmenopausal (interval between 1 y before the FMP and 2 y after the FMP), and postmenopausal (interval between 2 y after the FMP and 5 y after the FMP). 28 To illustrate these trajectories of bone loss relative to the FMP date, we present race-specific LOESS plots of baseline-normalized LS BMD as a function of months before and after the FMP ( Fig.) . We used baseline-normalized BMD for ease of interpretation: the slope in each phase represents change in BMD per year as a percentage of baseline BMD.
We modeled the slopes in each of the three segments of the piecewise model as functions of the primary exposure variable (phytonutrient tertiles) estimated at the SWAN visit closest to the starting point of each segment. Models were stratified by race/ethnicity and adjusted for age at FMP (and centered at the sample mean age at FMP, 51 y). Models were also adjusted for BMI (continuous; centered at race-specific mean values), total calorie intake (in kilocalories; continuous), supplemental calcium use (any vs none), supplemental vitamin D use (any vs none), cigarette use (any current vs other), and alcohol use (any current vs other); for each of these covariates, we used the values obtained at the start of each of the three segments of the piecewise model. Dietary isoflavone intake and all covariates were modeled as affecting each of the three slopes. In addition, baseline BMD was allowed to affect the three slopes to capture any independent influence of starting BMD on percentage declines in BMD during the three periods. We estimated the 10-year total effects of each primary exposure by linearly combining the slopes for each segment. Because the primary dietary exposure variables were dichotomized (highest tertile of phytonutrient vs other), to test the hypothesis that higher phytonutrient intake was related to the rate of bone loss in each segment, we estimated differences in slopes between the highest tertile and the lower tertiles. To account for within-woman correlation between repeated observations, we included random effects for the intercept and three slopes (allowing the intercept and slopes to vary from woman to woman).
Interaction analyses
Race/ethnicity-stratified cross-sectional and longitudinal models disclosed apparent differences in the relation between isoflavones and BMD in Japanese and Chinese women. One reason for these differences could have been higher isoflavone intake in Japanese women compared with Chinese women. To specifically explore the role of racial/ethnic differences in isoflavone intake, we created a combined sample that included both Japanese and Chinese women with comparable isoflavone intake (based on baseline data, ranging between 963 and 47,099 Kg/d). This combined sample included 186 of the original 236 Asian women. By eliminating extremes of exposure, this restriction eliminated collinearity between race and isoflavones. We formally tested for interaction between race and isoflavone exposure in the combined sample in both cross-sectional and longitudinal models by including a race Â menopausal transition stage Â isoflavone term in the crosssectional models and interactions of race with isoflavone for the intercept and all three slopes in longitudinal models.
RESULTS
The study sample consisted of 242 black, 384 white, 117 Chinese, and 119 Japanese participants. At baseline, the mean age of all participants was 46.2 years, the mean BMI was 27.5 kg/m 2 , and 58% of women were premenopausal. The remainder of the participants were early perimenopausal by design (Table 1) . Mean values of BMI and BMD were dissimilar among the four racial/ethnic groups.
Estimated dietary isoflavone consumption at baseline was bimodal: the lowest tertiles among Chinese or Japanese women barely overlapped with the highest tertiles among black or white women ( Table 2 ). The estimated isoflavone consumption of Asian participants was about 25 times greater than that of non-Asian women. Therefore, to conduct relational analyses, we used isoflavone tertiles for Asian (aggre-gated Chinese and Japanese) and non-Asian (aggregated black and white) groups.
For comparability with longitudinal results, cross-sectional analyses between baseline levels of isoflavone intake and baseline values of LS and FN BMD were restricted to the 853 participants in the longitudinal sample (Table 3 ). In multiply adjusted models in premenopausal Japanese women only, higher tertiles of isoflavone consumption were related to higher mean FN BMD values; there was an approximately 17% gradient in mean BMD ranging from the lowest tertile to the higher tertile to the highest tertile of isoflavone intake (P for trend = 0.0003). Among women in the three remaining racial/ethnic groups, no statistically significant associations were observed between isoflavone intake and BMD.
Our longitudinal analysis was framed on previously published longitudinal trajectories of BMD in SWAN: there was no detectable change in LS or FN BMD until 1 year before the FMP; bone loss began 1 year before the FMP and decelerated, but did not stop, 2 years after the FMP; trajectories of bone change were linear within each of the three time intervals in relation to the FMP date. 28 The first linear segment spanned between 5 years before the FMP and 1 year before the FMP (pretransmenopause). The second segment included the time interval between 1 year before the FMP and 2 years after the FMP (transmenopause). The final linear segment covered 2 years after the FMP to 5 years after the FMP (postmenopause). LOESS plots illustrated that trajectories of LS BMD relative to the FMP date were similar in each ethnic/racial group (Fig.) . FN BMD exhibited the same trajectory pattern as LS BMD (data not shown). Therefore, for the current longitudinal analyses of isoflavone intake and BMD change, we again used piecewise regressions, dividing LS and FN BMD trajectories into three linear segments in relation to FMP date. We tested the effects of tertiles of isoflavone intake on the slopes (changes in BMD) during each of the three time segments. Table 4 summarizes the results of piecewise linear models that quantified the changes in LS and FN BMD (slopes during each interval) during the pretransmenopausal, transmenopausal, and postmenopausal intervals. During the transmenopausal and postmenopausal periods, women of all racial/ethnic groups lost bone at both the LS and the FN, irrespective of their levels of isoflavone intake. This is evidenced by bone loss rates (slopes) in all groups that were statistically significantly less than zero.
In addition, isoflavone intake was related to change in BMD in Japanese women during one time interval (transmenopause). At the LS in Japanese women during the transmenopausal phase, women with higher isoflavone intake lost more bone presented as adjusted least-squares mean (95% CI) estimates for each menopause stage among women in each tertile of intake. Sample sizes: black, 242 (134 premenopausal); white, 384 (207 premenopausal); Chinese, 117 (79 premenopausal); Japanese, 119 (76 premenopausal). Isoflavone tertiles were defined for Asian (Chinese and Japanese) and non-Asian (African-American and Caucasian) women. Model was adjusted for age, body mass index, menopausal transition stage (premenopausal or early perimenopausal), alcohol use (any vs none), calcium use (any vs none), vitamin D use (any vs none), current smoking (any vs none), study site, and total calorie intake. BMD, bone mineral density. than women with lower intake (annualized rates of loss were j2.80%, j2.24%, and j1.94% for women in the highest tertile to the lowest tertile of isoflavone intake, P for trend = 0.01). Japanese women with higher isoflavone intake also lost more bone at the FN during the transmenopausal phase. Annualized rates of loss were j2.16%, j1.89%, and j1.04% for women in the highest tertile to the lowest tertile of isoflavone intake (P for trend = 0.04). In all other cases, BMD loss rates did not differ among isoflavone intake groups. In stratified models, we observed a positive association between baseline FN BMD and tertiles of isoflavone intake in Japanese, but not Chinese, women. In longitudinal stratified models, only Japanese women manifested higher rates of LS and FN bone loss during transmenopause in association with For relational analyses, isoflavone tertiles were defined for Asian (Chinese and Japanese) and non-Asian (African-American and Caucasian) women (see BMethods[).
The levels and slopes in each of the three phases were modeled as functions of the primary exposure (tertiles) and covariates. Models were stratified by race/ ethnicity and adjusted for age at FMP, baseline BMD, and the following time-varying covariates: body mass index (continuous), total calorie intake (in kilocalories; continuous), calcium supplement use (yes vs no), vitamin D supplement use (yes vs no), and cigarette use (current). Age at FMP was centered at the sample mean (51 y), and body mass index was centered at race/ethnicity-specific means. LS, lumbar spine; FN, femoral neck; BMD, bone mineral density; FMP, final menstrual period. high isoflavone intake. However, Japanese women also had the highest isoflavone consumption in our study. To formally test for a possible race-isoflavone interaction, we generated a subsample consisting of Chinese and Japanese women with overlapping isoflavone intake (between 963 and 47,099 Kg/d).
In this subgroup, isoflavone dose effect could be distinguished from race/ethnicity effect. In the combined Japanese and Chinese sample at baseline, higher isoflavone intake was associated with higher baseline BMD only in premenopausal Japanese women; no relation was found among premenopausal Chinese women (P for interaction = 0.0067; data not shown). In longitudinal models, isoflavone-ethnicity interaction was also statistically significant at the LS during the transmenopausal interval (P for interaction = 0.0194; data not shown) and was borderline significant at the FN (P for interaction = 0.1344; data not shown).
DISCUSSION
Using SWAN's three-phase model of bone loss in relation to the FMP as a starting point, we evaluated the impact of consumption (in tertiles) of dietary isoflavones on longitudinal change in BMD. The pretransmenopausal segment spans the period from 5 years before the FMP to 1 year before the FMP; during this time, no statistically significant change in LS or FN BMD was observed. During transmenopause (1 y before the FMP through 2 y after the FMP) and postmenopause (2 y after the FMP through 5 y after the FMP), women from all racial/ethnic groups lost bone. To assess whether isoflavone intake affected change in BMD during each of the three phases, we tested the hypothesis that rates of bone loss (slopes) would differ across isoflavone tertiles. That hypothesis was supported in one case: during transmenopause among Japanese women, greater LS and FN BMD loss was seen in association with greater isoflavone intake. Otherwise, tertiles of isoflavone intake were not related to rates of BMD loss.
That higher isoflavone intake was associated with higher FN peak bone mass in premenopausal, but not early perimenopausal, Japanese women agreed with the results of our first cross-sectional report, which relied on the limited phytonutrient database available to us at the time. 21 Concordant with our null cross-sectional results in Chinese women, a cross-sectional study of southern Hong Kong Chinese women reported no association between isoflavone intake and BMD in premenopausal women. 19 The mean intake in that study's top tertile was 53 mg, about twice that of the SWAN Chinese sample.
We observed a greater rate of LS BMD loss in association with higher isoflavone intake during transmenopause only in Japanese women. In SWAN, the trajectory of serum estrogen levels in relation to the FMP mirrored the trajectory of BMD change. 35 During the transitional interval, endogenous estrogens declined, but they did not reach the low levels characteristic of postmenopause. In the transitional phase, therefore, isoflavones may compete with endogenous estrogens, resulting in higher bone loss rates. 21 Comparator studies of dietary isoflavone intake and longitudinal change in BMD are rare. In one longitudinal analysis of data from Hong Kong Chinese women aged 30 to 40 years (roughly comparable with our pretransmenopause phase), higher soy isoflavone intake was related to lower rates of LS, but not FN, BMD loss during about 3 years of observation. 36 Allowing for differences in ascertainment, the Hong Kong study's top isoflavone quartile mean intake (15 mg) was reasonably comparable with our definition of high intake among Chinese women and the food sources were similar to those in SWAN. 27 The dissimilarity between the Hong Kong study results and the SWAN results may be attributable to interstudy differences in bone loss patterns, enabling the detection of effect in the former but not in the latter. In the Hong Kong study, the premenopausal LS bone loss rate averaged 3.5%, strikingly higher than the 0.6% per year observed for SWAN's premenopausal Chinese sample.
Both positive (higher peak BMD) and negative (greater transmenopausal loss) effects of high isoflavone intake were confined to Japanese participants. Several mechanisms may account for these unique associations in Japanese women, including racial/ethnic variations in the amount of isoflavone consumed, food sources of isoflavones, and/or isoflavone metabolic capacity. Intake was vastly greater in Asian women than in non-Asian women, but isoflavone consumption was even higher in Japanese women than in Chinese women. Our subanalysis of Chinese and Japanese women who had comparable isoflavone levels suggested that higher dose alone did not account for the observed Japanese-Chinese difference. Higher concentrations of isoflavones typify food items in the Japanese diet compared with the Chinese diet. 37, 38 Unlike the Chinese diet, the Japanese diet is rich in fermented soy food, such as tempeh, miso, and soy paste. Fermentation removes the isoflavone sugar moiety, creating an aglycone, which is absorbed faster and in greater amounts than the original glycoside (with sugar attached) form. 39 This potential explanation would need to be explored with a food-level analysis rather than an isoflavone-level analysis. The ability to metabolize isoflavones to active forms (eg, equol and p-ethyl phenol), which characterizes roughly 30% of white women and 50% of Asian women, may also underlie differences in the biological effects of isoflavones. 40<42 However, we know of no data that support a higher rate of isoflavone metabolic capacity in Japanese women compared with Chinese women.
Limitations of our study included the inescapable error in estimating nutrient intake. Even our expanded phytonutrient database was not exhaustive, causing underestimation, and isoflavone concentrations in soy crops varied, leading to inaccuracies. 27, 29 Nonetheless, relative rankings of nutrient intake are robust; importantly, differential misclassification is minimized by the SWAN diet assessment because it accommodates mixed dishes and accounts for ethnic foods. 27 We conducted multiple statistical tests of our a priori hypotheses. The isolated benefit of isoflavones on peak bone mass in Japanese women may have been attributable to chance, but we observed similar Japanese-only benefits of isoflavones on peak BMD in our prior study, providing some support for the current findings. 21 Our finding of a higher rate of BMD loss in Japanese women with higher isoflavone intake during the transmenopausal phase must also be viewed cautiously, given the many statistical comparisons. We could have used a simpler biological framework (eg, we could have examined the effects of isoflavones across the entire 10-y transition period rather than breaking the transition into three intervals). Although this simpler approach would have resulted in fewer statistical tests, it would have ignored what we know of the underlying biology: SWAN and other studies have demonstrated that bone loss and estrogen decline patterns are nonlinear during the 10-year interval surrounding the FMP. 28, 35, 43, 44 The ways in which isoflavones affect BMD may differ during these very different biological phases. 3, 4 ,6<10 Large differences in the consumption of high-isoflavone foods in Eastern and Western diets resulted in statistical methodological challenges. Collinearity between race and intake would have occurred if we created isoflavone tertiles based on the entire sample. We constructed Asian and non-Asian tertiles and conducted analyses in models stratified by race/ethnicity, recognizing that the definition of Bhigh[ isoflavone intake in black and white women differs greatly from that in Chinese and Japanese women.
CONCLUSIONS
In aggregate, in most instances, our study indicates no relation between dietary isoflavone intake and peak bone mass or rate of bone loss during the menopausal transition; thus, overall results do not support the hypothesis that usual levels of dietary isoflavone intake affect peak bone mass or bone loss during the menopausal transition. However, these analyses and our prior published work do suggest that higher dietary isoflavone intake has a fairly large positive effect on peak FN bone mass in Japanese women, and we newly report that higher isoflavone intake may have a modest detrimental effect on both LS and FN BMD loss during transmenopause in Japanese women, leading to more bone loss in this phase. 21 These findings must be interpreted in the context of the multiple tests that were necessary to evaluate the complex biological framework that we proposed. That we have found a race/ethnicity-specific effect of isoflavones suggests that there may be environmental and genetic variations in bone accretion and loss during the life course; the cumulative influence of isoflavones on bones may be the sum of their effects during each portion of the bone trajectory. Future work must examine the prevalence of isoflavone metabolic capacity in each racial/ ethnic group and whether this characteristic modifies the bone effects of dietary intake.
